IN2012DN02580A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02580A
IN2012DN02580A IN2580DEN2012A IN2012DN02580A IN 2012DN02580 A IN2012DN02580 A IN 2012DN02580A IN 2580DEN2012 A IN2580DEN2012 A IN 2580DEN2012A IN 2012DN02580 A IN2012DN02580 A IN 2012DN02580A
Authority
IN
India
Prior art keywords
mglur4
allosteric
compounds useful
glutamate receptor
receptor subtype
Prior art date
Application number
Other languages
English (en)
Inventor
P Jeffrey Conn
Craig W Lindsley
Corey R Hopkins
Charles David Weaver
Colleen M Niswender
Darren W Engers
Yiu-Yin Cheung
Patrick R Gentry
James M Salovich
Rocco D Gogliotti
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of IN2012DN02580A publication Critical patent/IN2012DN02580A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN2580DEN2012 2009-09-04 2010-09-07 IN2012DN02580A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24003109P 2009-09-04 2009-09-04
PCT/US2010/048030 WO2011029104A1 (en) 2009-09-04 2010-09-07 Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction

Publications (1)

Publication Number Publication Date
IN2012DN02580A true IN2012DN02580A (pt) 2015-08-28

Family

ID=43649686

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2580DEN2012 IN2012DN02580A (pt) 2009-09-04 2010-09-07

Country Status (12)

Country Link
US (1) US8779157B2 (pt)
EP (1) EP2473055A4 (pt)
JP (1) JP2013503909A (pt)
CN (1) CN102740699A (pt)
AU (1) AU2010289281A1 (pt)
BR (1) BR112012004919A2 (pt)
CA (1) CA2773038A1 (pt)
IL (1) IL218426A0 (pt)
IN (1) IN2012DN02580A (pt)
RU (1) RU2012114770A (pt)
SG (1) SG178999A1 (pt)
WO (1) WO2011029104A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2751176A1 (en) 2009-01-28 2010-08-05 Vanderbilt University Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8759377B2 (en) 2009-11-23 2014-06-24 Vanderbilt University Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
MA38885B1 (fr) * 2013-09-25 2018-11-30 Hoffmann La Roche Dérivés d'éthynyle modulateurs allosteriques positifs (pam) du recepteur metabotropique du glutamate 4 (mglu4)
EP2853532B1 (en) 2013-09-28 2020-12-09 Instytut Farmakologii Polskiej Akademii Nauk 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
TWI649310B (zh) * 2014-01-10 2019-02-01 赫孚孟拉羅股份公司 乙炔基衍生物
TWI576340B (zh) * 2014-02-25 2017-04-01 赫孚孟拉羅股份公司 乙炔基衍生物
WO2016115272A1 (en) 2015-01-13 2016-07-21 Vanderbilt University Benzothiazole and benzisothiazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
WO2016123627A1 (en) 2015-01-30 2016-08-04 Vanderbilt University Isoquiniline and napthalene-substituted compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction
US10526323B2 (en) 2015-01-30 2020-01-07 Vanderbilt University Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
EP3271353B1 (en) * 2015-03-19 2019-11-27 H. Hoffnabb-La Roche Ag 3-(4-ethynylphenyl)hexahydropyrimidin-2,4-dione derivatives as modulators of mglur4
US9987242B2 (en) 2015-05-05 2018-06-05 Northwestern University Treatment of Levodopa-induced Dyskinesias
MX2018000592A (es) 2015-07-15 2018-04-24 Hoffmann La Roche Derivados de etinilo como moduladores del receptor de glutamato metabotropico.
PE20190382A1 (es) 2016-07-18 2019-03-08 Hoffmann La Roche Derivados etinilo
US10710997B2 (en) 2016-09-01 2020-07-14 Vanderbilt University Isoquinoline amide and isoquinoline amide-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US10294222B2 (en) 2016-09-01 2019-05-21 Vanderbilt University Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
WO2018089546A1 (en) 2016-11-08 2018-05-17 Vanderbilt University Isoquinoline ether compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
WO2018089544A1 (en) 2016-11-08 2018-05-17 Vanderbilt University Isoquinoline amine compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US11319304B2 (en) 2017-06-28 2022-05-03 Vanderbilt University Pyridine quinoline compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
SG11202001264UA (en) 2017-08-16 2020-03-30 Univ Vanderbilt Indazole compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
EP3827001A1 (en) 2018-07-26 2021-06-02 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK529378A (da) 1978-01-09 1979-07-10 Shell Int Research Anilidderivater
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2725206B1 (fr) 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US6355664B1 (en) 1997-03-03 2002-03-12 Boehringer Ingelheim Pharmaceuticals, Inc. Phenylpyrrolidines, phenylimidazolidines, 3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease
USRE38132E1 (en) 1997-03-03 2003-06-03 Boehringer Ingelheim Pharmaceuticals, Inc. Phenylpyrrolidines, phenylimidazolidines,3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease
FR2764889B1 (fr) 1997-06-20 2000-09-01 Sod Conseils Rech Applic Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
US6809088B2 (en) 1997-03-24 2004-10-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
US6335445B1 (en) 1997-03-24 2002-01-01 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
US7138526B1 (en) 1999-06-15 2006-11-21 Aventis Pharmaceuticals Inc. Solid phase synthesis of n,n-disubstituted diazacycloalkylcarboxy derivatives
US6353013B1 (en) 1999-07-21 2002-03-05 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
US6365615B1 (en) 1999-07-21 2002-04-02 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
CA2393466C (en) 1999-12-21 2010-01-19 Gpi Nil Holdings, Inc. Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
JP2004535411A (ja) 2001-05-25 2004-11-25 ブリストルーマイヤーズ スクイブ カンパニー マトリックスメタロプロテナーゼ及び/またはTNF−α転換酵素(TACE)の阻害剤としてのヒダントイン及び関連複素環化合物
DE60234264D1 (de) 2001-10-01 2009-12-17 Bristol Myers Squibb Co Spiro-hydantoin-verbindungen, die sich als entzündungshemmende mittel eignen
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
EP1542686A4 (en) 2002-07-31 2006-10-18 Euro Celtique Sa ARYL-SUBSTITUTED HYDANTOIN COMPOUNDS AND THEIR USE AS SODIUM CHANNEL BLOCKERS
US7053112B2 (en) 2002-09-24 2006-05-30 Schering Aktiengesellschaft Imidazolidinedione analogs useful as anticoagulants and antithrombotics
KR20060032633A (ko) 2003-07-11 2006-04-17 엘비온 아게 벤조디아제핀 수용체의 알파 3 서브유닛에 대한 선택성을갖는 화합물을 사용한 중추신경계 장애의 치료 또는 예방방법
WO2005030128A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Pyrazole modulators of metabotropic glutamate receptors
MY139887A (en) * 2004-04-02 2009-11-30 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same.
US7932250B2 (en) 2004-07-01 2011-04-26 Daiichi Sankyo Company, Limited Thienopyrazole derivative having PDE7 inhibitory activity
UY29896A1 (es) 2005-11-04 2007-06-29 Astrazeneca Ab Nuevos derivados de cromano, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
WO2008017381A1 (de) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
GB0713686D0 (en) * 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
AR068784A1 (es) 2007-10-16 2009-12-02 Novartis Ag Derivados de imidazolidinas, procesos de preparacion, composiciones farmaceuticas que los comprenden y su uso como modulador de los receptores npy y y2.

Also Published As

Publication number Publication date
BR112012004919A2 (pt) 2019-09-24
AU2010289281A1 (en) 2012-04-12
RU2012114770A (ru) 2013-10-10
EP2473055A1 (en) 2012-07-11
SG178999A1 (en) 2012-04-27
EP2473055A4 (en) 2013-02-13
JP2013503909A (ja) 2013-02-04
IL218426A0 (en) 2012-04-30
WO2011029104A1 (en) 2011-03-10
US8779157B2 (en) 2014-07-15
US20120245153A1 (en) 2012-09-27
CA2773038A1 (en) 2011-03-10
CN102740699A (zh) 2012-10-17

Similar Documents

Publication Publication Date Title
IN2012DN02580A (pt)
MX2012013031A (es) Potenciadores alostericos mglur4 de sulfona heterociclica, composiciones y metodos para tratar disfuncion neurologica.
MY181898A (en) Heterocyclic compounds and uses thereof
MX341825B (es) Compuestos de heteroarilo y usos de los mismos.
MX2010008714A (es) Derivados de amida como moduladores alostericos positivos y metodos de uso de los mismos.
GB201017345D0 (en) Receptor antagonists
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
GT201300164A (es) Derivados de biciclo (3.2.1.) octilamida y sus usos
MY153975A (en) Pyridine derivatives as s1p1/edg1 receptor modulators
EP2569330A4 (en) CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF
TN2012000195A1 (en) Solid dispersion of rifaximin
MY161170A (en) Pyrimidine cyclohexyl glucocorticoid receptor modulators
MX2009009415A (es) Compuestos de tetrahidroisoquinolina como moduladores del receptor h3 de la histamina.
MX2009007284A (es) Cd200 y su receptor, cd200r, modulan la masa osea por medio de la diferenciacion de osteoclastos.
MY146506A (en) Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
IN2012DN02876A (pt)
HK1167404A1 (en) Benzothiadiazepine derivatives used as ampa and nmda receptor modulators ampa nmda
WO2009089234A3 (en) Substituted dibenzhydrylpiperazines
HK1142608A1 (en) 5-pyridinone substituted indazoles and pharmaceutical compositions thereof 5-
EP2477631A4 (en) SUBSTITUTED PHENYLAMINE CARBOXAMIDE ANALOGUES AS NEGATIVE ALLOSTERIC MGLUR5 MODULATORS AND METHOD FOR THEIR PREPARATION AND USE
EP2670731A4 (en) POSITIVE ALLOSTERIC MODULATORS OF THE NICOTINE ACETYLCHOLIN RECEPTOR ALPHA 7 AND USES THEREOF
MX2010005488A (es) Compuestos de cicloalquiloxi y heterocicloalquiloxipiridina como moduladores del receptor h3 de histamina.
EP2576575A4 (en) PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, THEIR METHODS OF MANUFACTURE AND USES THEREOF
WO2009132119A3 (en) Substituted oxazolidinones
IN2012DN01379A (pt)